발행물

논문
컨퍼런스

전체 논문

9

1

Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer
김지원, 최용준, 최문경, 박재우, 박미소, 김명준, 이재선, 오수진, 이영주, 심완섭, 김명진, 김용철, 강건욱
BIOMEDICINE & PHARMACOTHERAPY, 2024

2

PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia
김지원, 최용준, 박재우, 최효이, 오수진, 박진희, 박미소, 김윤균, 김용철, 김명진, 강건욱
BIOMEDICINE & PHARMACOTHERAPY, 2023

3

The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression
Yone K Lin, Nehal Gupta, Hanbing Song, Wei Wu, Rovingaile K Ponce, 김지원, Ross A Okimoto, Eric J Small, Felix Y Feng, Franklin W Huang
ELIFE, 2022

4

Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer
Yone Kawe Lin, 김지원, Wei Wu, Nehal Gupta, Rovingaile Kriska Ponce, Cuyler Luck, Ross A Okimoto
CELL REPORTS, 2022

5

Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR
Kim, JW (Kim, Ji Won), Yadav, DK (Yadav, Dharmendra K, Kim, SJ (Kim, Soo Jin), Lee, MY (Lee, Moo-Yeol), Park, JM (Park, Jung-Min), Kim, BS (Kim, Bum Seok), Kim, MH (Kim, Mi-hyun), Park, HG (Park, Hyeung-geun), Kang, KW (Kang, Keon Wook)
ENDOCRINE-RELATED CANCER, 2019

6

Inhibition of tumor growth and angiogenesis of tamoxifen‑resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor
김지원, 자야 가우탐, 김지은, 김정애, 강건욱
Oncology letters, 2019

7

Role of the CYP3A4-mediated 11,12-epoxyeicosatrienoic acid pathway in the development of tamoxifen-resistant breast cancer
김지원, 응구엔티투이푸옹, 김정애, 전장수, 이지윤, Wen Jun Xu, 양진원, 김상겸, 강건욱
Oncotarget, 2017

8

Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer
김지원, 박미소
TOXICOLOGICAL RESEARCH, 2024

9

The role and application of transcriptional repressors in cancer treatment
Miso Park, 김지원, Keon Wook Kang
ARCHIVES OF PHARMACAL RESEARCH, 2023